In Brief: Circon rejects U.S. Surgical bid
This article was originally published in The Gray Sheet
Executive Summary
Circon rejects U.S. Surgical bid: U.S. Surgical says Aug. 16 it will continue its $18-per-share tender offer for minimally invasive urological and gynecological surgical products firm Circon despite a recommendation from Circon's board that its shareholders reject the bid, launched Aug. 2 ("The Gray Sheet" Aug. 5, p. 3). In an Aug. 15 press release, Circon says its board determined that the company "should continue to pursue its strategic plan and that Circon is not for sale at this time." The USSC offer "does not reflect the long-term values inherent in the company and in the opinion of Bear Stearns, Circon's financial advisor, the consideration offered is inadequate," Circon notes. To help stave off the takeover attempt, Circon's board adopts a shareholder rights plan, to be distributed to stockholders of record on Aug. 26. The rights become exercisable if "a person tenders for or acquires 15% or more of Circon's common stock," the company says. U.S. Surgical's tender bid expires on Aug. 29...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.